Clinical trial · Observational
Cardiac Impairments Following Pediatric Cardiotoxic Anti-cancer Treatment
Early Detection of Cardiac Impairments Following Cardiotoxic Anti-cancer Treatment During Childhood and Adolescence - A Feasibility Study
NCT05261256CI-TRIAL-00122821completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims at investigating the feasibility of recruitment and application of a method regarding early detection of subclinical changes in cardiac health after completion of acute cancer treatment during childhood and adolescence.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cardiovascular Diseases | — | UNRESOLVED | — |
| Pediatric Cancer | Childhood Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Exercise stress echocardiography | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Participants treated for pediatric cancer
- description
- This group includes children, adolescents and young adults treated for pediatric cancer who received anthracyclines and/or chest radiation during treatment.
- interventionNames
- Diagnostic Test: Exercise stress echocardiography
- label
- Healthy control subjects
- description
- This group includes healthy children, adolescents and young adults without a history of pediatric cancer as age-and gender-matched control subjects.
- interventionNames
- Diagnostic Test: Exercise stress echocardiography
Primary outcomes (5)
- measure
- Feasibility Criteria 1 - Recruitment Rate
- timeFrame
- Throughout study completion, an average of 2 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 10 Years
- Maximum age
- 25 Years
Show eligibility criteria text
Inclusion criteria for all participants: * Aged between 10 and 25 years * Body height of ≥1,40m (required for performing the examination on the semi supine bicycle ergometer) * Signed informed assent (minor participant) and consent (legal guardian and full-aged participant) Additional inclusion criteria for participants following cancer treatment: * Completion of acute cancer treatment with anthracyclines and/or chest radiation * End of treatment 12 months and five years ago (± three months) * Medical approval for study participation Additional inclusion criteria for healthy control subjects: \- Appropriate as matched pair with respect to age and gender Exclusion Criteria: * Known cardiovascular diseases (incoherent with cardiotoxic treatment) * Inability to follow study instructions (e.g., mental retardation, language) * Acute orthopedic injury (e.g., bone fracture) or orthopedic impairments that preclude examination on a bicycle ergometer (e.g., instable prosthetic device) All participants receive a basic physical and cardiological examination at rest as part of the study protocol to ensure capability before performing the exercise stress echocardiography.
References
Publications (0)
Data not yet available
No reference posted for this study.